Pfizer/Protalix file Gaucher's disease therapy in EU
This article was originally published in Scrip
Executive Summary
Pfizer and Protalix BioTherapeutics have filed their investigational Gaucher's disease enzyme replacement therapy taliglucerase alfa with the European Medicines Agency (EMA).